Charles River Laboratories Intl. Inc vs Xcel Energy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $303.09 (market cap $14.23B), while Xcel Energy Inc trades at $73.46 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 3.2× Charles River Laboratories Intl. Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Xcel Energy Inc for 61 Days on average.
| CRL | XEL | |
|---|---|---|
Market Cap | $14.23B | $45.82B |
Volume | 1,176,885 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $310.77 | $83.91 |
52-Week Low | $149.93 | $69.39 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $17.06B | $84.14B |
Dividend Yield | — | 3.23% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Xcel Energy (XEL) trades at $73.46, up 1.44% today, with a bullish technical signal and consensus analyst target of $90.83 suggesting 24% upside. Recent earnings show mixed beats, with Q2 2026 EPS of $0.93 exceeding expectations. The company maintains solid profitability with a 15.28% net margin and benefits from rising data center power demand, though it faces capital expenditure pressures with a $60 billion investment plan.
The outlook is positive, driven by infrastructure investments and load growth, but risks include high debt levels, wildfire liabilities, and interest rate sensitivity. Wall Street sentiment is bullish with 63% buy ratings, but valuation concerns persist with a P/E of 20.1 above some peers.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →